metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Genotipo y expresión fenotípica de la hemocromatosis hereditaria en España
Información de la revista
Vol. 27. Núm. 8.
Páginas 437-443 (enero 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. 8.
Páginas 437-443 (enero 2004)
Acceso a texto completo
Genotipo y expresión fenotípica de la hemocromatosis hereditaria en España
Genotype and phenotypic expression of hereditary hemochromatosis in spain
Visitas
6597
A. Pardoa,**
Autor para correspondencia
equinter@doymanet.es

Correspondencia: Dr. A. Pardo. Servicio de Aparato Digestivo. Hospital Universitario de Canarias. Ofra, s/n. 38320 La Laguna. Tenerife. España.
, E. Quinteroa, Y. Barriosa, M. Bruguerab, L. Rodrigoc, C. Vilad, D. Aceroe, C. Guarnerf, S. Pascualg, L. Lópezh, R. Morenoi, E. Fábregaj, R. Andradek, G. Peláezl, J. Santosm, M. Butin, M. Torresñ, por el Grupo de Hemocromatosis Hereditaria de la AEEH *
a Hospital Universitario de Canarias. La Laguna. Tenerife. España
b Hospital Clínic i Provincial. Barcelona. España
c Hospital Central de Asturias. Oviedo. España
d Hospital del Mar. Barcelona. España
e Hospital Dr. Josep Trueta. Girona. España
f Hospital de la Santa Creu i Sant Pau. Barcelona. España
g Hospital General Universitario. Alicante. España
h Hospital de San Agustín. Avilés. Oviedo. España
i Hospital de La Princesa. Madrid. España
j Hospital Marqués de Valdecilla. Santander. España
k Facultad de Medicina. Universidad de Málaga. Málaga. España
l Hospital Torre Cárdenas. Almería. España
m Hospital Germans Trias i Pujol. Badalona. Barcelona. nHospital General Vall d'Hebron. Barcelona
n Hospital de l'Esperit Sant. Santa Coloma de Gramenet. Barcelona. España
Ver más
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Introducción

La prevalencia de homocigosidad para C282Y en pacientes con hemocromatosis hereditaria (HH) originarios de algunos países de la cuenca mediterránea puede ser sustancialmente inferior a la observada en el norte de Europa. Los datos referidos a España son contradictorios y basados en series pequeñas de ámbito regional. El objetivo de nuestro estudio es determinar la prevalencia de las 2 principales mutaciones del gen HFE en una serie de pacientes españoles con HH, no relacionados y de diferente procedencia geográfica.

Pacientes y mÉtodo

Los criterios para el diagnóstico de HH fueron: índice de saturación de transferrina superior al 45% en 2 determinaciones y homocigosidad para C282Y y/o índice de hierro hepático mayor de 1,9 de tejido hepático seco en pacientes no cirróticos o superior a 4,1 en presencia de cirrosis. Se excluyeron los casos detectados en familiares. Se evaluaron los datos demográficos, la expresión clínica, los parámetros del hierro y las mutaciones C282Y y H63D del gen HFE en un total de 222 pacientes.

Resultados

El 83,3% de los pacientes fueron homocigotos para C282Y y el 5% dobles heterocigotos (C282Y/H63D). No se observaron diferencias significativas en la expresión fenotípica ni en la frecuencia de homocigosidad para C282Y en los pacientes nacidos en el norte o en el sur de España.

Conclusión

El patrón genotípico y la expresión fenotípica de la HH en España son muy similares a los observados en el norte de Europa. Por tanto, la heterogeneidad genética descrita en algunas regiones del sur de Europa no puede considerarse una característica común a todos los países de la cuenca mediterránea.

Introduction

The prevalence of C282Y homozygosity in patients with hereditary hemochromatosis (HH) has been reported to be markedly lower in the Mediterranean Basin than in northern Europe. In Spain, the available data are contradictory and limited to small series in specific regions. The objective of this study is to determine the prevalence of the 2 main HFE gene mutations in a large series of unrelated Spanish patients with HH from different geographical origins.

Patients and Method

The criteria for HH diagnosis were: repeat serum transferrin saturation index (> 45% plus C282Y homozygosity and/or hepatic iron index (> 1.9 of dry liver weight in non-cirrhotic patients or (> 4.1 in patients with liver cirrhosis. Cases in related individuals were excluded. Demographic data, clinical expression, iron parametersand HFE gene mutations (C282Y and H63D) were assessed in 222 patients.

Results

A total of 83.3% of patients were C282Y homozygous and 5% were compound heterozygous (C282Y/H63D). No significant differences in phenotypic expression or in the frequency of C282Y homozygosity were observed between patients born in the North and South of Spain.

Conclusion

The genotypic and phenotypic expression of HH in Spain is very similar to that reported in Northern Europe. Thus, the genetic heterogeneity described in some Southern European regions cannot be considered a common feature to all countries of the Mediterranean Basin.

El Texto completo está disponible en PDF
Bibliografía
[1.]
S.A. Harrison, BR. Bacon.
Hereditary hemochromatosis: update for 2003.
J Hepatol, 38 (2003), pp. S14-S23
[2.]
C. Niederau, R. Fischer, A. Purschel, W. Stremmel, D. Haussingr.
Long-term survival in patients with hereditary hemochromatosis.
Gastroenterology, 92 (1996), pp. 208-212
[3.]
J.N. Feder, A. Gnirke, W. Thomas, Z. Tsuchihashi, D.A. Ruddy, A. Basava, et al.
A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis.
Nat Genet, 13 (1996), pp. 399-408
[4.]
E. Beutler, T. Gelbart, C. West, P. Lee, M. Adams, R. Blackstone, et al.
Mutation analysis in hereditary hemochromatosis.
Blood Cells Mol Dis, 22 (1996), pp. 187-194
[5.]
P.C. Adams, S. Chakrabarti.
Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria.
Gastroenterology, 114 (1998), pp. 319-323
[6.]
E.C. Jazwinska, L.M. Cullen, F. Busfield, W.R. Pyper, S.I. Webb, L.W. Powell, et al.
Hemochromatosis and HLA-H.
Nat Genet, 14 (1996), pp. 249-251
[7.]
K.J. Robson, M. Worwood, JD. Shearman.
A simple genetic test identifies 90% of UK patients with hemochromatosis. The UK Hemochromatosis Consortium.
Gut, 41 (1997), pp. 841-844
[8.]
C. Datz, M.R.A. Lalloz, W. Vogel, T. Graziadei, F. Hackl, G. Vautier, et al.
Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic hemochromatosis.
J Hepatol, 27 (1997), pp. 773-779
[9.]
E.M. Cardoso, P. Stal, K. Hagen, J.M. Cabeda, S. Esin, M. De Sousa, et al.
HFE mutations in patients with hereditary haemochromatosis in Sweden.
J Intern Med, 243 (1998), pp. 203-208
[10.]
P.A. Gochee, L.W. Powell, D.J. Cullen, D. Du Sart, E. Rossi, JK. Olynik.
A population based study of the biochemical and clinical expression of the H63D hemochromatosis mutation.
Gastroenterology, 122 (2002), pp. 646-651
[11.]
M. Carella, L. D'Ambrosio, A. Totaro, A. Grifa, M.A. Valentino, A. Piperno, et al.
Mutation analysis of the HLA-H gene in Italian hemocromatosis patients.
Am J Hum Genet, 60 (1997), pp. 828-832
[12.]
A. Piperno, M. Sampietro, A. Pietrangelo, C. Arosio, L. Lupica, G. Montosi, et al.
Heterogeneity of hemochromatosis in Italy.
Gastroenterology, 114 (1998), pp. 996-1002
[13.]
N. Borot, M. Roth, L. Malfroy, C. Demangel, J. Vinel, J. Pascal, et al.
Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients.
Immunogenetics, 5 (1997), pp. 371-375
[14.]
G. Papanikolaou, M. Politou, E. Terpos, S. Fourlemadis, N. Sakellaropoulos, D. Loukopoulos, et al.
Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity.
Blood Cells Mol Dis, 26 (2000), pp. 163-168
[15.]
M. Sanchez, M. Bruguera, J. Bosch, J. Rodes, F. Ballesta, R. Oliva, et al.
Prevalence of the Cys282Tyr and His63Asp gene mutations in Spanish patients with hereditary hemocromatosis and in controls.
J Hepatol, 29 (1998), pp. 725-728
[16.]
M. Sanchez, M. Bruguera, E. Quintero, Y. Barrio, R. Mazzara, J. Rodes, et al.
Hereditary hemochromatosis in Spain.
Genet Test, 4 (2000), pp. 171-176
[17.]
P. Guix, A. Picornell, M. Parera, C. Tomas, J. Muncunill, J.A. Castro, et al.
Prevalence of the C282Y mutation for haemochromatosis on the Island of Majorca.
Clin Genet, 58 (2000), pp. 123-128
[18.]
E. Fabrega, B. Castro, L. Sanchez-Castro, A. Benito, J.L. Fernandez-Luna, F. Pons-Romero.
Prevalencia de la mutacion Cys282Tyr del gen de la hemocromatosis en pacientes diagnosticados de hemocromatosis hereditaria de Cantabria.
Med Clin (Barc), 112 (1999), pp. 451-453
[19.]
D. De Juan, A. Reta, A. Castiella, J. Pozueta, A. Prada, E. Cuadrado.
HFE gene mutations analysis in Basque hereditary haemochromatosis patients and controls.
Eur J Hum Genet, 9 (2001), pp. 961-964
[20.]
F. Jorquera, A. Dominguez, V. Diaz-Golpe, J. Espinel, F. Munoz, A. Herrera, et al.
Mutaciones C282Y y H63D del gen de la hemocromatosis en pacientes con sobrecarga ferrica.
Rev Esp Enf Dig, 93 (2001), pp. 293-302
[21.]
EASL International Consensus Conference on Hemochromatosis.
J Hepatol, 33 (2000), pp. 485-504
[22.]
J.K. Olynyk, D.J. Cullen, S. Aquilia, E. Rossi, L. Summerville, LW. Powell.
A population based study of the clinical expression of the hemocromatosis gene.
N Engl J Med, 341 (1999), pp. 718-724
[23.]
A. Asberg, K. Hveem, K. Thorstensen, E. Ellekjeter, K. Kannelonning, U. Fjosne, et al.
Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons.
Scand J Gastroenterol, 36 (2001), pp. 1108-1115
[24.]
E. Beutler, V.J. Felitti, J.A. Koziol, N.J. Ho, T. Gelbart.
Penetrance of 845G š¨ A (C282Y) HFE hereditary hemochromatosis mutation in the USA.
[25.]
S.J. Cotler, M.P. Bronner, R.D. Press, T.H. Carlson, J.D. Perkins, M.J. Emond, et al.
End-stage liver disease without hemochromatosis associated with elevated hepatic iron index.
J Hepatol, 29 (1998), pp. 257-262
[26.]
N.J. Shaheen, B.R. Bacon, IS. Grimm.
Clinical characteristics of hereditary hemochromatosis patients who lack the C282Y mutation.
Hepatology, 28 (1998), pp. 526-529
[27.]
D. Guyader, C. Jacquelinet, R. Moirand, B. Turlin, M.H. Mendler, J. Chaperon, et al.
Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis.
Gastroenterology, 115 (1998), pp. 929-936
[28.]
A. Piperno, C. Arosio, L. Fossati, M. Vigano, P. Trombini, A. Vergani, et al.
Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis.
Gastroenterology, 119 (2000), pp. 441-445
[29.]
C. Camaschella, A. Roetto, A. Cali, M. DeGobbi, G. Garozzo, M. Carella, et al.
The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.
Nat Genet, 25 (2000), pp. 14-15
[30.]
A. Roetto, A. Totaro, A. Piperno, A. Piga, F. Longo, G. Garozzo, et al.
New mutations inactivating transferrin receptor 2 in hemochromatosis type 3.
Blood, 97 (2001), pp. 2555-2560
[31.]
D. Girelli, C. Bozzini, A. Roetto, F. Alberti, F. Daraio, R. Colombari, et al.
Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene.
Gastreonterology, 122 (2002), pp. 1295-1302
[32.]
G. Montosi, A. Donovan, A. Totaro, C. Garuti, E. Pignatti, S. Cassanelli, et al.
Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.
J Clin Invest, 108 (2001), pp. 619-623
[33.]
J.C. Barton, R. Sawada-Hirai, B.E. Rothenberg, RT. Acton.
Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands.
Blood Cells Mol Dis, 25 (1999), pp. 147-155
[34.]
P. Aguilar-Martinez, C. Esculie-Coste, M. Bismuth, M. Giansily-Blaizot, D. Larrey, JF. Schved.
Transferrin receptor-2 gene and non-C282Y homozygous patients with hemochromatosis.
Blood Cells Mol Dis, 27 (2001), pp. 290-293
[35.]
D.F. Wallace, P. Pedersen, J.L. Dixon, P. Stephenson, J.W. Searle, L.W. Powell, et al.
Novel mutation in ferroportin 1 is associated with autosomal dominant hemochromatosis.
Blood, 100 (2002), pp. 692-694
[36.]
V. Devalia, K. Carter, A.P. Walker, S.J. Perkins, M. Worwood, A. May, et al.
Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3).
Blood, 100 (2002), pp. 695-697
[37.]
P.L. Lee, C. Halloran, C. West, E. Beutler.
Mutation analysis of the transferring receptor-2 gene in patients with iron overload.
Blood Cells Mol Dis, 72 (2001), pp. 85-89
[38.]
S. Cassanelli, E. Pignatti, G. Montosi, C. Garuti, M. Mariano, D. Campioli, et al.
Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy.
J Hepatol, 34 (2001), pp. 523-528
[39.]
P. Guix, A. Picornell, M. Parera, A. Galmes, A. Obrador, M.M. Ramon, et al.
Distribution of HFE C282Y and H63D mutations in the Balearic Islands (NE Spain).
Clin Genet, 61 (2002), pp. 43-48
[40.]
S. Alvarez, M.S. Mesa, F. Bandres, E. Arroyo.
C282Y and H63D mutation frequencies in a population from central Spain.
Dis Markers, 17 (2001), pp. 111-114
[41.]
G. Lucotte.
Frequency analysis and allele map in favor of the celtic origin of the C282Y mutation of hemochromatosis.
Blood Cells Mol Dis, 27 (2001), pp. 549-556
[42.]
A. Piazza, S. Rendine, E. Minch, P. Menozzi, J. Mountain, L. Cavalli-Sforza.
Genetics and the origin of European languages.
Proc Natl Acad Sci U S A, 92 (1995), pp. 5836-5840
[43.]
L. Quintana-Murci, R. Veitia, M. Fellous, O. Semino, ES. Poloni.
Genetic structure of Mediterranean populations revealed by Ychromosome haplotype analysis.
Am J Phys Anthropol, 121 (2003), pp. 157-171
[44.]
R. Scozzari, F. Cruciani, A. Pangrazio, P. Santolamazza, G. Vona, P. Moral, et al.
Human Y-chromosome variation in the western Mediterranean area: implications for the peopling of the region.
Hum Immunol, 62 (2001), pp. 871-884
[45.]
J.C. Barton, N.H. Barton, TJ. Alford.
Diagnosis of hemochromatosis probands in a community hospital.
Am J Med, 103 (1997), pp. 498-503
[46.]
B.R. Bacon, S. Sadiq.
Hereditary hemochromatosis: diagnosis in the 1990šfs.
Am J Gastroenterol, 92 (1997), pp. 784-789
[47.]
R. Moirand, P.C. Adams, V. Bicheler, P. Brissot, Y. Deugnier.
Clinical features of genetic hemochromatosis in women compared with men.
Ann Intern Med, 127 (1997), pp. 105-110

Al final del artículo se ofrece el listado completo de los centros e investigadores participantes.

Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos